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Abstract
Background. Quality indicators for dialysis care vary
across countries and regions, but regional variability
across centres has received little attention. We analysed
variations in quality indicators among dialysis facilities
in western Switzerland to identify opportunities for
improving care for patients with end-stage kidney
disease.
Methods. A cross-sectional study of 617 dialysis
patients treated at 19 facilities examined the distribu-
tion of indicators of quality of care addressing:
adequacy of dialysis (Kt/V 1.2 for haemodialysis,
Kt/V 2 for peritoneal dialysis), anaemia control
(haemoglobin 110 g/l), calcium and phosphate
control (product 4.4mmol2/l2), adequate nutrition
(serum albumin >35 g/l), hypertension control (pre-
dialysis blood pressure <140/90mmHg) and type
of vascular access. Centre quality targets were the
following: achievement of quality criteria for 80%
of their patients, except 85% for anaemia control
and 60% for arterio-venous ﬁstulae.
Results. Most centres fulﬁlled quality targets for
dialysis adequacy, but substantial variations existed
among centres (haemodialysis, 76%, range 36–100;
peritoneal dialysis, 76%, range 33–100). Results were
similar for anaemia (77%, range 35–100), calcium
phosphate product (69%, range 29–92), albumin
(63%, range 26–95), hypertension control (33%,
range 13–54) and arterio-venous ﬁstula (61%, range
49–92). The between-centre variability was signiﬁ-
cantly greater than would be expected by chance, for
all indicators. Dialysis facilities with >40 patients
better fulﬁlled quality targets than university-based
centres. Adjustment for patient characteristics did not
modify these results.
Conclusions. Substantial variations in quality indi-
cators existed between dialysis centres in western
Switzerland, which could not be attributed to dif-
ferent centre policies, or to differences in available
measures of patient case mix. These ﬁndings
indicate opportunities for improvement in dialysis
practice which may translate into improved clinical
outcomes.
Keywords: dialysis; end-stage renal failure;
quality assessment; quality of care
Introduction
The quality of care provided to dialysis patients
is under increasing scrutiny. Since the 1990s,
dialysis practice guidelines have been developed
and disseminated, both in the USA [1,2] and in
Europe [3,4], and systematic measurements of
clinical performance, relying on indicators such as
levels of Kt/V, haematocrit and serum albumin, have
been implemented. These indicators have gained
acceptance both because they reﬂect the quality of
relevant health care processes (i.e. amount of
dialysis, treatment of anaemia, nutrition level) and
because they correlate with patient mortality and
morbidity [5–7].
Earlier studies have revealed striking regional
differences in the distributions of such indicators,
both across dialysis networks in the USA [8]
and among countries in international comparisons [9].
The differences are not fully explained by patient
characteristics, suggesting variations in the quality of
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care. However, studies that focus on regional or
national averages fail to capture possible differences
in quality indicators between dialysis centres within
a given region. Between-centre variations in quality
of care have received only limited attention so far.
In particular, a recent study has shown that the
implementation of a quality improvement programme
reduces between-centre variability in quality indicators
[10]. Understanding between-centre variability in
clinical performance is important for the identiﬁcation
of best practices in dialysis care.
The aim of the present study was to compare
quality of care indicators between dialysis facilities
in an area—western Switzerland—where access to
health care is virtually unrestricted, and where the
population is culturally and ethnically homogenous.
Furthermore, we adjusted these comparisons for
patient characteristics, in order to clarify whether
patient case mix could explain part of the observed
differences in quality indicators.
Subjects and methods
Setting
Western Switzerland has a population of 1.7 million
inhabitants. The prevalence of dialysis treatment for
end-stage renal disease (ESRD) is between 329 and 476 per
million inhabitants [11]. Twenty-one dialysis units (18 in the
French-speaking area and three in the German-speaking area)
treat patients with ESRD. Three units are privately owned,
16 are in the public sector and two belong to tertiary care
hospitals.
Study design
A cross-sectional evaluation of all patients with end-stage
renal failure (ESRF) on all forms of chronic dialysis was
performed in March 2001 for the 18 French-speaking centres
and in June 2001 for the three German speaking-centres.
Two months prior to the study, a resource guidebook was
provided to the centres, containing selected internationally
recognized guidelines and recommendations on dialysis
quantity and modalities, anaemia, nutritional status, calcium
and phosphate metabolism and vascular access [3,12–15]. A
multidisciplinary team of the University Hospitals in Geneva
and Lausanne led this project. Participation of all dialysis
centres was voluntary. The project was approved by the
research ethics committees of the Universities of Lausanne
and Geneva.
Data collection
We collected patient-level data by means of a questionnaire,
completed by the centre team based on each patient’s
medical and nursing records, and centre-level data using
a questionnaire, completed by the medical director and
head nurse. In addition, patients ﬁlled in a self-report
questionnaire regarding their satisfaction with their care
and health status, the results of which will be reported
elsewhere.
Patient-level data
Quality criteria were deﬁned for individual patients in six
domains of clinical care:
1. Dialysis adequacy: for haemodialysis patients, the Kt/V
was calculated using the single pool Daugirdas II method,
based on post-dialysis plasma samples drawn after slowing
the blood pump to 50ml/min for 2min; a sp (single pool)
Kt/V 1.2 was considered adequate. For peritoneal
dialysis patients, weekly Kt/V and creatinine clearances
were determined according to classical kinetic modelling of
peritoneal transport, and a weekly Kt/V 2 was con-
sidered adequate.
2. Appropriate anaemia management: assessed by achieved
levels of haemoglobin or haematocrit. A haemoglobin
110 g/l or a haematocrit 33% were considered ade-
quate. When several measures were recorded during the
past month, the average was used for the determination.
3. Calcium and phosphate metabolism: assessed by the
calcium phosphate product. A value of 4.4mmol2/l2
was considered to be adequate using pre-dialysis serum
calcium and phosphorus levels.
4. Nutrition: assessed by the serum albumin. A level >35 g/l
was considered to be a criterion of good nutrition.
5. Vascular access: deﬁned by the the presence of a native
arterio-venous ﬁstula, a synthetic graft or a catheter.
Dialysis via a native arterio-venous ﬁstula was considered
optimal.
6. Hypertension was deﬁned as a mean pre-dialysis blood
pressure over 1 week of >140/90mmHg.
To better understand the aetiology of possible deviations
from the recommended criteria for some of the quality
indicators, we also recorded the mean dose of recombinant
human erythropoietin per week and its mode of administra-
tion, measurements of ferritin and transferrin saturation,
levels of serum alkaline phosphatase and serum intact
parathormone (PTH), use of phosphate binders and
vitamin D, the body mass index, and the date of creation
and type of vascular access (arterio-venous ﬁstula, graft,
tunnelled and non-tunnelled catheters).
Finally, we also requested for each patient descriptive
and clinical data: age, gender, time on renal replacement
therapy, current dialysis modality, pre-dialysis nephrologist
referral, placement on waiting list for transplantation, cause
of renal failure and presence of medical conditions that allow
computation of the modiﬁed Charlson co-morbidity index.
This index gives a score of 1 for all forms of coronary artery
disease as well as congestive heart failure, peripheral vascular
and cerebrovascular diseases, dementia, chronic pulmonary
disease, connective tissue disorder, peptic ulcer disease,
mild liver disease and diabetes. Hemiplegia, diabetes with
organ damage, any tumour, leukaemia and lymphoma
received a score of 2. Moderate or severe liver disease were
scored 3, and AIDS or metastatic solid tumour were scored 6.
We added 2 for ESRF and 1 for each decade>40 years of age.
This index was recently validated for predicting outcomes and
costs in dialysis patients [16].
Centre-level data
Centre-level data were obtained by averaging values across
all patients treated by each centre. Percentages of patients
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expected to fulﬁl a quality criterion (quality targets) were
derived from Canadian and European guidelines for anaemia
management (85%) and native ﬁstula prevalence (60%). They
were set arbitrarily to 80% for dialysis adequacy, calcium and
phosphate metabolism, and nutrition.
Furthermore, we obtained a description of each centre
for routine clinical practices such as target dose of delivered
dialysis, anaemia treatment, calcium/phosphorus manage-
ment policies, vascular access monitoring and blood pressure
control (Table 1).
Patient census, medical stafﬁng and nursing workload
were recorded as well as the main interventions for each
quality indicator (mean erythropoietin dose for anaemia
correction, dietitian support for albumin and control of
CaP product, dialysis duration and ﬁstula prevalence
for dialysis adequacy (Table 2). Centres were also classiﬁed
into three categories: University-based centres, centres with
40 patients and centres with <40 patients.
Data analysis
For dichotomous patient-level variables, such as whether a
patient fulﬁls a given quality criterion, we report centre-level
proportions in the total patient population, as well as the
mean proportion in each centre, and the mean and SD of
centre means. The centre means and SDs were weighted
in proportion to the centre census size. For continuous
variables, we report the mean and SD, or quantiles (25th,
50th and 75th) for skewed distributions.
We used logistic regression modelling to determine if
patient characteristics inﬂuenced between-centre compari-
sons. The dependent variable was the fulﬁlment of each
quality of care criterion, and the regression coefﬁcients for
each centre were adjusted for patient age, gender, duration
of dialysis and Charlson co-morbidity index. We derived
the adjusted proportions of patients who fulﬁlled each
quality criterion from these models. Then, we computed
a Pearson correlation coefﬁcient between the unadjusted
and the adjusted proportions. To take into account intra-
centre characteristics, we performed an analysis that con-
sidered each centre as a cluster of observations using a
generalized estimating equation. This procedure estimates
SEs that are corrected for lack of independence between
observations.
All data analyses were performed using SPSS for Windows
(version 11.0, Chicago, IL) and Stata (version 8.2; College
Station, TX).
Results
Data collection
Data were obtained from all 21 centres in western
Switzerland. Demographic, clinical and laboratory
information was recorded by centre nurses and
nephrologists for all 617 patients dialysed in March
(French-speaking centres) and June 2001 (German-
speaking centres). Data from two centres treating only
one patient at the time of the survey (Chaˆteau d’Oex
and Division de Ne´phrologie Pe´diatrique, CHUV
Lausanne) were aggregated to those of the CHUV
Lausanne for the purpose of analysis. Retrieval of data
for individual patients took between 25 and 45min
per patient. Patient questionnaires were veriﬁed for
missing or improbable data (30% of the question-
naires), which were subsequently added or rectiﬁed.
Centre characteristics
Centres treated a median of 23 haemodialysis patients
(range 6–75), and were equipped with a median of
10 dialysis beds (range 3–26, total 190). There were two
University-based centres which treated 158 patients
in total, ﬁve centres with 40 patients which treated
238 patients and 12 centres with <40 patients which
treated 221 patients. In the nine units performing
peritoneal dialysis, a median of six peritoneal dialysis
patients (2–23, total 64) were treated per centre.
Median nursing workload was 54 dialysis sessions/
nurse/month (range 33–68).
Median medical stafﬁng was 0.5 physician/
10 patients (range 0.1–1.1) (Table 2).
All units had reverse osmosis-based, water prepara-
tion systems, and all implemented mixed (heat and
chemical) disinfection procedures of the water treat-
ment system. Routine measures for infection preven-
tion (vascular access care, patient isolation and
vaccination procedures) were comparable among the
centres, but routine vaccination against pneumococcus
was implemented in only nine centres. Only one centre
had a dialyser reuse policy. The target dose of delivered
dialysis (sp Kt/V) was 1.2 for 17 centres, 1.4 for
three centres (one centre did not specify a target dose)
Table 1. Standards for routine clinical practices and implementa-
tion in 21 dialysis centres in western Switzerland, 2001 (Chateau
d’Oex and Ne´phrologie Pe´diatrique CHUV centres are included in
this analysis)
Routine practices Frequency suggested
according to [4], [9],
[12], [13], [15]
Centres
with criteria
fulﬁlled
Dialysis adequacy
Haemodialysis: Kt/V
measurement
Monthly 14/21
Peritoneal dialysis:
measurement
of weekly Kt/V and
creatinine clearance
Every 4 months 1/9
Anaemia management
Haemoglobin and/or
haematocrit measurement
Monthly 21/21
Iron stores measurement Every 3 months 21/21
Prevention of
hyperparathyroidism
Calcium measurement Monthly 19/21
Phosphate measurement Monthly 19/21
PTH measurement Every 6 months 16/21
Nutritional assessment
Serum albumin measurement Monthly 5/21
Nutritional assessment by
at least two methods
Every 6 months 10/21
Vascular access monitoring
Physical examination Weekly 11/21
Fistula/graft ﬂow monitoring Every 2 months 5/21
Blood pressure control
Blood pressure measurement At each session 21/21
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and/or URR 65% in all units. All centres treated
anaemia with erythropoietin (subcutaneously in 94%
of the patients) and intravenous iron, with a target
haemoglobin of 110 g/l in 15 centres and 100 g/l in four
centres (two centres did not specify a target dose). Iron
stores were considered adequate when the ferritin level
was >200 IU/l in 13 centres. All centres aimed to
maintain serum phosphorus levels below 2mmol/l and
calcium levels between 2.25 and 2.50mmol/l, with the
help of phosphate binders and vitamin D. Aluminium
salts were not used routinely. As no speciﬁc guidelines
on blood pressure control in dialysis patients were
available at the time of the study, hypertension control
was characterized as a pre-dialysis blood pressure of
<140/90mmHg according to JNC VI.
Patients characteristics
Almost all patients (98%) were Caucasian, a slight
majority was male, and the mean age was 64 years
(Table 3). Hypertensive nephropathy was the leading
cause of ESRD, and vascular disease was the most
prevalent co-morbid condition. Diabetes was diagnosed
as the main cause of ESRD in 15% of our patients but,
when included as a co-morbidity factor, was present in
nearly one-third of them. The mean modiﬁed Charlson
index was 7.6 (SD 3.1).
Two out of ﬁve patients were referred late for dialy-
sis (late referral was deﬁned as <1 month prior to
implementing dialysis) (Table 3). Most patients were
treated by haemodialysis, and the median duration
of renal replacement therapy was 3 years. The mean
haemodialysis duration was 218min/session.
Quality of care indicators
For all six indicators, the majority of patients satisﬁed
the individual quality criteria, with proportions
ranging from 61% (arterio-venous ﬁstula) to 77%
(for anaemia control), save for control of hypertension
which was only 33% (Table 4). However, the con-
formity rate varied considerably across centres
(Figure 1). This variation was statistically signiﬁcant
for all indicators (all P<0.001). Less than half of the
dialysis centres fulﬁlled each of the centre quality
targets (Table 4). Overall, no centre fulﬁlled all six
centre quality targets, one (5%) fulﬁlled four targets,
three (16%) fulﬁlled three targets, nine (47%) fulﬁlled
two targets, ﬁve (26%) fulﬁlled one target and one (5%)
centre fulﬁlled none.
Case mix
Fulﬁlment of individual quality criteria varied little
with patient characteristics (Table 5). Older patients
and women had a higher calcium phosphate product
than younger patients and men. Women also had
fewer native arterio-venous ﬁstulae. Patients with the
highest co-morbidity score were more anaemic and
those with a duration of dialysis >2 years were more
adequately dialysed but more likely to have low
albumin levels. Blood pressure control was inadequate
in >66% of our patients and was inversely correlated
with the Charlson score for co-morbidities.
Table 4. Overall results of indicators of quality for patients and centres in western Switzerland (March 2001)
Criterion Mean (SD, range) Individual
target for
quality criterion
Proportion
of patients
fulﬁlling
target
Centre quality
target
Mean (SD, range)
of weighted centre
means
No. of
centres
fulﬁlling
target
Kt/V (HD patients) 1.37 (0.3, 0.4–4.28) 1.2 400/529 (75.6%) 80% of patients 75.6 (9.0, 36–100) 8/19
Kt/V (PD patients) 12.48 (0.8, 1.5–6.2) 2.0 42/55 (76.4%) 80% of patients 76.4 (13.7, 33–100) 6/9
Haemoglobin or
haematocrit
119 (12.5, 73–151) or
35.9 (3.7, 21–46)
110mg/dl or
33%
473/617 (76.7%) 85% of patients 76.7 (7.7, 35–100) 6/19
Calciumphosphate
product
3.9 (1.1, 0.7–8.7) 4.4 mmol2/l2 420/610 (68.9%) 80% of patients 68.9 (5.5,29–92) 4/19
Albumin 36.1 (5.9, 13–72) 35 g/l 386/610 (63.3%) 80% of patients 63.3 (9.0, 26–95) 4/19
Native AVF prevalence – Prevalent 336/553 (60.8%) 60% of patients 60.8 (5.6, 49–92) 9/19
Blood pressure control 145/77 (21/12, 70–220/37–114) 140/90 201/617 (32.6%) 80% of patients 32.6 (9.0, 13–54) 0/19
Table 3. Demographic characteristics of dialysed patients in
western Switzerland (March 2001)
No. of patients 617
Age (years, mean±SD) 63.7±15
Patients >70 years old (%) 39.9
Male gender (%) 62
Late referral (%) 37.8
Causes of renal failure (%)
Hypertensive nephropathy 31
Diabetes (unique diagnosis) 15
Glomerulonephritis 15
Interstitial nephritis 14
Polycystic kidney disease 11
Others 16
Smokers (%) 21
Physical disability (%) 17
Cerebrovascular disease/coronary heart
disease/peripheral vascular disease (%)
53
Cancer (%) 14
Diabetes (%) 28
Body mass index between 20 and 25 (%) 48
Body mass index <20 (%) 14
Modiﬁed Charlson’s co-morbidity index (mean±SD) 7.6±3.1
Patients on the waiting list for transplantation (%) 21
Patients hospitalized in the previous 3 months (%) 36
1858 P. Saudan et al.
0
2
4
6
8
10
Hemoglobin > 110 g/l
0
2
4
6
8
10
Albumin > 35 g/l
0
2
4
6
8
10
Kt/v > 1.2
0
2
4
6
8
10
Phosphocalcic product < 54 mg/dl
Less than 50% 50 to 59% 60 to 69% 70 to 79% 80 to 89% 90 to 100%
Arteriovenous fistula
0
2
4
6
8
10
0
1
5
15
Controlled blood
Percentage of patients in a dialysis centre who fulfill the criterion
Fig. 1. Distribution of the centres by adjusted prevalence of conformity with indicators of quality for the six domains of clinical care in the
19 dialysis centres of western Switzerland.
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We computed adjusted centre conformity rates
for the six indicators, adjusting for age, gender,
modiﬁed Charlson index, duration of renal replacement
therapy and size of facilities. Among the 19 centres,
the correlation coefﬁcients between unadjusted and
adjusted conformity rates for the ﬁve indicators were
between 0.98 and 1.00, suggesting that adjustment was
unnecessary.
Differences in the prevalence for three indicators
(absence of anaemia, albumin and Kt/V) were found
between larger (>40 patients) dialysis units vs smaller
units and university-based dialysis units (Table 5).
Using university-based dialysis units as the reference
group, odds ratios for absence of anaemia were 2.2
[95% conﬁdence interval (CI) 1.1–4.5] in the >40
patients dialysis units and 0.8 (95% CI 0.4–1.5) in the
<40 patients dialysis units. For normoalbuminaemia,
odds ratios were 6.4 (95% CI 1.9–22.1) in the >40
patients dialysis facilities and 1.0 (95% CI 0.4–2.9)
in the <40 patients dialysis units.
For dialysis adequacy, odds ratios were 2.1 (95% CI
1.0–4.6) in the >40 patients dialysis facilities and
1.6 (95% CI 0.8–3.2) in the <40 patients dialysis units.
Discussion
The main ﬁnding from this study was that quality
of care indicators varied considerably among
haemodialysis units of western Switzerland, even
though the aggregate ﬁndings for the region demon-
strated facility-level characteristics only modestly
below pre-deﬁned targets. The variability in quality
indicators contrasts with the rather homogeneous
treatment and management policies reported by the
centres. Centres had similar approaches to the mea-
surement of dialysis quantity, anaemia evaluation,
and calcium and phosphate metabolism. Assessment
of nutritional status was, however, not performed
according to published recommendations in most
dialysis units. Though effective interventions differed
between centres, there was no obvious correlation
with the results of target indicators.
Several patient characteristics were associated
with the achievement of quality criteria. In particular,
men were more likely than women to have an arterio-
venous ﬁstula, and healthier patients were less likely
to be anaemic. Patients with the briefest duration of
Table 5. Conformity to quality criteria according to patient characteristics (patient age, gender, co-morbidity score and duration of
renal replacement therapy) and size of dialysis facility
Dialysis
adequacy,
n (%)
Absence of
anaemia,
n (%)
Albumin
>35g/l, n (%)
CP product
4.4mmol2/l2,
n (%)
AV ﬁstula
(HD patients),
n (%)
Controlled blood
pressure, n (%)
Age (n) P¼ 0.61 P¼ 0.66 P¼ 0.30 P¼ 0.03a P¼ 0.56 P¼ 0.06
<55 (149) 104 (74.3) 115 (77.2) 95 (64.4) 93 (63.3) 81 (64.8) 49 (32.8)
56–65 (140) 99 (75.0) 106 (75.7) 89 (64.0) 97 (69.8) 73 (57.5) 58 (41.4)
66–75 (176) 129 (76.8) 134 (76.1) 105 (60.7) 114 (65.5) 102 (63.4) 49 (27.8)
75 (152) 110 (76.4) 118 (76.6) 90 (59.6) 116 (77.3) 80 (58.0) 45 (29.8)
Gender (n) P<0.002b P¼ 0.27 P¼ 0.22 P¼ 0.02c P¼ 0.04d P¼ 0.66
Males (384) 257 (70.6) 300 (78.3) 242 (64.0) 105 (27.6) 223 (64.1) 128 (33.3)
Females (233) 185 (84.1) 173 (74.3) 137 (59.1) 85 (37) 113 (55.1) 73 (31.3)
Charlson score (n) P¼ 0.25 P¼ 0.009e P¼ 0.52 P¼ 0.06 P¼ 0.16 P¼ 0.005f
2–5 patients (151) 106 (74.7) 119 (78.8) 99 (66.0) 97 (65.1) 85 (65.9) 61 (40.4)
6–7 patients (157) 120 (79.7) 131 (83.4) 95 (61.3) 106 (68.0) 93 (65.0) 59 (37.6)
8–9 patients (152) 112 (78.3) 117 (77.0) 94 (63.5) 98 (64.9) 75 (54.7) 41 (26.9)
10 patients (157) 104 (70.3) 106 (67.5) 91 (58.0) 119 (77.3) 83 (57.6) 40 (25.5)
RRT duration (n) P<0.001g P¼ 0.79 P¼ 0.01h P¼ 0.16 P¼ 0.96 P¼ 0.15
1–2 years (165) 89 (57.8) 128 (77.6) 77 (47.5) 124 (76.6) 83 (60.1) 53 (32.1)
3–4 years (185) 143 (80.8) 139 (75.1) 57 (30.1) 117 (63.6) 102 (61.1) 66 (35.7)
5–8 years (142) 111 (83.5) 107 (75.4) 49 (35.0) 100 (71.4) 81 (61.4) 42 (29.6)
9 years (125) 99 (82.5) 99 (79.2) 48 (38.7) 79 (64.8) 70 (60.3) 40 (32.0)
Size (n, range) P<0.005i P<0.001i P<0.001i P<0.55 P<0.59 P<0.23
University (158, 69–89) 96 (66.2) 115 (72.8) 77 (50) 102 (65.4) 73 (57) 43 (27.2)
>40 patients (238, 40–57) 191 (80.9) 204 (85.7) 201 (84.8) 166 (70.3) 128 (61.2) 80 (33.6)
<40 patients (221, 6–27) 155 (76.3) 154 (69.7) 101 (46.1) 152 (69.7) 135 (62.5) 78 (35.2)
All P-values are calculated using the score test for trend of odds.
aOlder patients have a lower CP product.
bFemale patients have a better dialysis adequacy.
cMale patients have a lower CP product.
dFemale patients have fewer native AVFs.
ePatients with the highest Charlson score were more anaemic.
fBlood pressure control was associated with a smaller Charlson score.
gShort duration of RRT was associated with less dialysis adequacy.
hShort duration of RRT was associated with a higher albumin level.
iAbsence of anaemia, normoalbuminaemia and dialysis adequacy were associated with non-university-based facilities treating 40 patients.
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ESRD in our population were less likely to suffer
from hypoalbuminaemia, which is in agreement with
a previously published observation [17]. Adjustment
for patient characteristics changed centre-level results
very little. This suggests that the dialysed population
in the participating centres is similar, and that in this
particular instance, adjustment for patient case mix is
not necessary for meaningful between-centre compari-
sons. We found that centres having >40 patients
scored better than university-based centres in terms
of dialysis adequacy, absence of anaemia and normo-
albuminaemia. These better results probably reﬂect
the increased prevalence of incident patients in the
university-based dialysis centres. The differences
between centres with >40 patients and smaller centres
is more difﬁcult to explain since neither centre policies
nor patient characteristics appear to explain this
variation. In particular, the great variability in human
resources among the centres did not correlate with
the variation observed in quality of care indicators
(Table 2). The availability of the nephrologist may play
a role since in the larger centres the medical staff
are more important. Another possible explanation is
that the patient characteristics included in our adjust-
ment models failed to include important determinants
of quality indicators, and that better adjustment
models would have decreased residual inter-centre
variability. However, it is unclear to us what these
hidden confounding variables might be. An alternative
explanation could be that centre policies as reported
do not truly reﬂect how care is delivered to patients in
daily practice, and that these clinical practices vary
from one centre to another despite stated policies
being globally the same. Furthermore, differences
in family support or income may also contribute to
the variation in the achievement of quality criteria.
Unfortunately, we did not obtain this information
in our study. Other explanations have to be found
for the well-known hurdles to translate guidelines into
clinical practice, i.e. resources availability, physician
behaviour, etc.
Generally, the results observed in the western Swiss
centres matched those observed elsewhere. Dialysis
adequacy in our patients (both haemodialysis and
peritoneal dialysis 76%) was midway between the levels
observed in the USA (haemodialysis 86%, peritoneal
dialysis 69%) and The Netherlands (haemodialysis
59%) [18,19]. Our patients were slightly older than
their US counterparts, but the proportion of patients
with a functional arterio-venous ﬁstula is considerably
higher than in the USA. We believe that adequacy of
dialysis should improve in our region as nephrologists
become more aware of the recommended threshold
for the Kt/V.
Anaemia management in our patients nearly reached
the target identiﬁed by the European Best Practice
Guideline (EBPG) 5 (target of >11 g/dl for 85% of
the population) [3,20]. Two factors may have con-
tributed to this ﬁnding. First, European guidelines
on anaemia treatment were published in 1999, well
before our study was conducted, and anaemia treat-
ment in haemodialysed patients has received much
attention in the interim. Secondly, most facilities in
our area also participated in the European Survey on
Anaemia Management (ESAM) study in the 1990s.
Understandably, most of our nephrologists were fully
aware of the haemoglobin target of 110–120 g/l in
this population.
Calcium and phosphate metabolism as well as the
nutritional status of our patients were areas with the
largest opportunity for improvement. One-third of our
patients had an elevated serum calcium phosphate
product. Similar results have been reported in Italy [21].
These parameters have been linked to an increased
risk of cardiovascular mortality, and lowering their
levels in dialysed patients is crucial. However, mild
phosphate and calcium disturbances are often asymp-
tomatic, and aggressive use of phosphate binders and
active vitamin D sterols to treat secondary hyper-
parathyroidism and hyperphosphataemia is commonly
hampered by the risk of hypercalcaemia.
Hypo-albuminaemia was observed in 37% of our
patients, well above the 20% found in a French
cooperative study [17]. Although serum albumin was
shown to predict mortality in dialysis patients, it is
also related to factors other than nutrition, such as
liver disease and inﬂammatory states. It also has to
be mentioned that the nephelometric method which
gives lower results was used in almost all units.
Nevertheless, the absence of a nutritional assessment
by two methods in nearly 80% of the patients and
absence of widespread nutritional support indicate
a deﬁciency in care. Indeed, a dietitian was available
only part-time in most of the facilities, which
may explain the fairly low standard of nutritional
care in our patients.
Concerning vascular access, our results (61%
patients with an arterio-venous ﬁstula) are midway
between European (80%) and American (24%) results
reported by the Dialysis Outcomes and Practice
Patterns (DOPPS) survey [22]. Fistula prevalence
varied considerably among centres in our area, ranging
from 49 to 92% of the patients. This probably reﬂects
local habits or availability of surgeons dedicated to
arterio-venous ﬁstula surgery, but may also reﬂect a
lack of implementation of guidelines in some centres.
Blood pressure seems adequately controlled in only
one-third of our patients. Moreover, cardioprotective
medications such as angiotensin-converting enzyme
inhibitors (ACEIs)/angiotensin II receptor blockers
and b-blockers were given only to one in three patients
in our dialysed population (Table 6). As these medica-
tions have been proven to reduce the elevated
cardiovascular mortality in these patients, their use
should be more widespread in dialysis patients.
Globally, the majority of the participating centres
(15 out of 19) achieved only two or fewer of the six
quality targets, and none achieved all six. Therefore,
there is still room for improvement. We believe
that development and systematic implementation of
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validated practice guidelines will eventually lead to
a global improvement in health care for dialysis
patients in western Switzerland.
Our study has several strengths and limitations. The
cross-sectional design does not afford a prospective
assessment of quality of care, and may not be as
effective as periodic monitoring of quality indicators
at stimulating improvement projects in treatment
facilities [23,24]. On the other hand, enrolment of
every patient on dialysis, as opposed to a sample,
ensured that even the smallest units felt themselves
to be partners of the project, and avoided opportunities
for patient selection bias. Nevertheless, facility-level
results based on small numbers of observations are
imprecise, e.g. if eight out of 10 patients meet the
quality criterion, the exact conﬁdence interval on the
adequacy proportion is 43–97%, if 24 of 30 patients
meet the criterion, the interval shrinks to 61–92%, and
if 80 of 100 do, the interval is 71–87%. This lack of
precision limits the utility of the feedback given
to individual centres. Implementation of guidelines
provided only 2 months prior to the study may have
been difﬁcult for some dialysis facilities. Finally,
the usefulness of evaluation of quality of care is
markedly reduced if it is not followed by a continuous
quality improvement programme within dialysis
facilities [25]. This would necessitate implementation
of an educational programme across the public and
private dialysis treatment sectors, demonstrating pro-
viders’ strong commitment to evidence-based guide-
lines and enhancing their capacity to measure quality
of care and to act on observed deﬁciencies [25].
A randomized controlled trial has shown that an
intervention focused on dialysis adequacy and tailored
to overcome speciﬁc barriers, such as shortened
treatment time, use of catheters and insufﬁcient
prescribed dialysis dose, can be successful over a
6 month period [26].
In conclusion, we described substantial variations
in six quality indicators among dialysis facilities of
western Switzerland. We could not attribute these
variations to discordant treatment policies, nor to
differences in patient case mix. Better standardization
and repeated evaluation of treatment goals and
processes, according to recognized clinical practice
guidelines, with the help of a national registry for
dialysis patients, would be likely to reduce the
variability we observed, and potentially improve the
quality of care.
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